Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00846053 · ClinicalTrials.gov registry record · NA

FDG-PET Imaging in Young Cystic Fibrosis Patients

A NA study of Cystic Fibrosis, sponsored by Washington University School of Medicine.

Completed
Registry status
NA
Development phase
21
Enrollment target
1
Study location

NCT00846053: Completed NA study of Cystic Fibrosis, sponsored by Washington University School of Medicine.

NCT00846053 is a NA study of Cystic Fibrosis that has completed, run by Washington University School of Medicine. The registered enrollment target is 21 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00846053, a NA study of Cystic Fibrosis, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
NA
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to determine how a person's lungs will uptake \[18F\]fluorodeoxyglucose (FDG), as measured with positron emission tomography (PET) scanning in young cystic fibrosis (CF) patients.

Primary Outcome

The whole lung kinetic influx constant (Ki) is the primary outcome measure that is derived from the time-activity curves, which are generated from regions of interest placed over the whole lungs. Therefore, a single time-activity curves from each scan is used to derive the Ki.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST FDG-PET

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2009-02
Est. Completion 2012-02
Phase NA

What the finished NCT00846053 record still lists

NCT00846053 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which FDG-PET is the first listed.

NCT00846053 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT00846053 about?

NCT00846053 is a clinical study titled "FDG-PET Imaging in Young Cystic Fibrosis Patients". The purpose of this research is to determine how a person's lungs will uptake \[18F\]fluorodeoxyglucose (FDG), as measured with positron emission tomography (PET) scanning in young cystic fibrosis (CF) patients.

What is the current status of trial NCT00846053?

This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2009-02. Estimated completion is 2012-02.

What conditions does trial NCT00846053 study?

This clinical trial studies the following conditions: Cystic Fibrosis.

What interventions are being tested in trial NCT00846053?

The interventions under investigation include: FDG-PET (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT00846053?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00846053 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00846053's enrollment target sits among peer trials

21 127th of 169 higher than 41 of 169 other Cystic Fibrosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00846053, the US trial registry maintained by the National Library of Medicine. NCT00846053 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.